Pfizer announces three-pronged pursuit of growth

11 July 2018

From the beginning of 2019, Pfizer (NYSE: PFE) will be split into three units.

The US pharma giant announced on Wednesday that its operations will be divided into an Innovative Medicines business – to include biosimilars and a new hospital arm for anti-infectives and sterile injectables – as well as an off-patent branded and generic Established Medicines unit operating with substantial autonomy within Pfizer, and a Consumer Healthcare division.

In May, Pfizer announced that it had not received an acceptable offer for its Consumer Healthcare business, and the Financial Times attributes the failure to sell this unit as the reason for the reorganization, though evidently this was not mentioned by the group chairman and chief executive, Ian Read, in his statement.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK